Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q2 2016 Earnings Presentation
10 slides from Anika Therapeutics's earnings presentation, Jul 28, 2016
Slide 1: Anika Therapeutics Second Quarter 2016 Earnings Call Presentation
ANIKA THERAPEUTICS, INC. Second Quarter 2016 Earnings Call Presentation July 28, 2016
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT The statements made in this presentation that are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements involve known a
Slide 3: Long-Term Growth Strategy
LONG-TERM GROWTH STRATEGY Expanding Advancing Strengthening Strategic Globally Pipeline Infrastructure M&A 3
Slide 4: Expanding Globally & Advancing Pipeline
EXPANDING GLOBALLY & ADVANCING PIPELINE • 1st Combination HA and Steroid in a Single Injection for Pain Associated with Knee OA • Rapid and Long Lasting Relief of Pain Symptoms • Commercialized in Canada and EU; In U.S. Regulatory Process Market Opportunity: ~$2 Billion 4
Slide 5: Advancing Pipeline: HYALOFAST
ADVANCING PIPELINE * • Non-woven HA Biodegradable 3D Scaffold for Cartilage Repair • Cost-effective Single-step Procedure for the Repair of Articular Cartilage Defects • Over 7,000 Treated with HYALOFAST Internationally • FastTRACK Phase III Trial Ongoing for U.S. Approval * In Pipeline in the U.S.;
Slide 6: Advancing Pipeline: Hip OA
ADVANCING PIPELINE • Expanding Product Indication for Treatment of Hip OA Pain • IDE Sponsored by U.S. Commercial Partner DePuy Synthes • Potential to be First Therapy to Market for Hip Indication • Phase III Trial Ongoing Market Opportunity: ~$600M* * In the U.S. 6
Slide 7: Advancing Pipeline: Tendinopathy
ADVANCING PIPELINE Tendinopathy: Repetitive Overuse Injuries to Soft and Connective Tissue Components of Joints • New Program Leveraging Injectable HA Technology • Received FDA Approval for IDE to Conduct Phase III Trial for Lateral Epicondylosis “Tennis Elbow” • Patient Enrollment to Commence in Q4
Slide 8: Advancing Growth Strategy
ADVANCING GROWTH STRATEGY Strengthening Infrastructure • Integration of Manufacturing Operations is on track; Build-out Substantially Complete • Construction on New European Headquarters in Padova, Italy underway Strategic M&A • Pursuing Opportunities to Augment Pipeline, Commercial Capabilities, or
Slide 9: Delivering Strong Growth
DELIVERING STRONG GROWTH Q2 2016 Financial Highlights Q2 Q2 1H 1H • Total revenue increased 16% 2015 2016 2015 2016 year-over-year Total Revenue $22.9 $26.6 $38.4 $48.9 • Orthobiologics revenue grew 21% year-over-year Net Income $7.8 $8.6 $11.3 $15.5 • Net income increased 10% year-over-year Diluted
Slide 10: Q&A
Q&A Anika Therapeutics, Inc. Second Quarter 2016 Earnings Call Presentation July 28, 2016